In addition, IL17A influences liver disease by modulating immune responses, with increased levels of IL17A correlating with worsening liver disease in MASH and hepatocellular carcinoma (HCC) [38]. Here, IL17A is linked to metabolic dysfunction-associated steatohepatitis.